Dr Caleb Alexander examines the US Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's Disease.
There is a market for direct-to-consumer genetic testing and a need for better consumer information and more regulation of tests and testing laboratories.